NDAORALSOLUTION
Approved
Nov 2020
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
3
Data completeness
5/8 — Partial
THYQUIDITY (levothyroxine sodium) by Pfizer is synthesis. First approved in 2020.
Drug data last refreshed 2h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
THYQUIDITY is an oral liquid formulation of levothyroxine sodium, a synthetic thyroid hormone replacement approved by the FDA in November 2020. It treats hypothyroidism by supplementing deficient thyroid hormone, with T4 converting peripherally to the active T3 form that binds nuclear thyroid receptors to regulate gene transcription and metabolic processes. The liquid formulation offers improved bioavailability and dosing flexibility compared to traditional tablets.
$0.054BPart D
Peak5.0 years to LOEThe product is in peak commercial phase with stable Medicare spending, indicating established market presence and potential for sustained team headcount in brand and field roles.
Mechanism of Action
synthesis. Triiodothyronine (T 3 ) and levothyroxine (T 4 ) diffuse into the cell nucleus and bind to thyroid receptor proteins attached to DNA. This hormone nuclear receptor complex activates gene transcription and synthesis of messenger RNA and cytoplasmic proteins. The physiological actions of…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (3)
Bioequivalence of Two Formulations of Levothyroxine Sodium 200 Micrograms (mcg) Under Tablet Form
Started Jun 2019
72 enrolled
Healthy
Levothyroxine Sodium in Thyroidectomized Patients Taking Proton Pump Inhibitors
Started Jul 2018
66 enrolled
Hypothyroidism;Postablative
Study of Dose Adjustment From Levothyroxine to a New Levothyroxine Sodium Test Formulation
Started Jul 2013
101 enrolled
Hypothyroidism
Career Relevance
Worked on THYQUIDITY at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.